ABT-737

Catalog No.S1002

ABT-737 Chemical Structure

Molecular Weight(MW): 813.43

ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.

Size Price Stock Quantity  
In DMSO USD 384 In stock
USD 120 In stock
USD 200 In stock
USD 570 In stock
USD 970 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 88 Publications

14 Customer Reviews

  • Cardiomyocytes transduced with or without Ad-Mst1 were treated with ABT-737 (0, 0.1, 1, 10 uM) for 12 hours. Representative immunoblots with antibodies to p62/SQSTM1, LC3 and GAPDH are shown.

    Nat Med 2013 19(11), 1478-88. ABT-737 purchased from Selleck.

    BCL-XL mediates human neutrophil survival. PMNs were preincubated with the BH3 mimetic ABT-737 (1–10 μM), then cultured in normoxia (gray bars) with or without GM-CSF (500 U/ml) or hypoxia (white bars)or 20 hours, and apoptosis was assessed by morphology (n = 4).

     

     

    J Clin Invest 2011 121, 1053-1063. ABT-737 purchased from Selleck.

  • Release of mitochondrial cytochrome c and loss of mitochondrial membrane potential after exposure to ABT-737 (100nM) for 2 hours were assessed by immunohistochemistry and staining with TMRE (red, top panels) and anti-CD41/FITC (green, top panels). Bar represents 5 um. Note that control cells display spreading on glass slides, whereas ABT-737-treated cells do not.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

    Platelets were incubated in HBS with or without ABT-737 (100nM) for 2 hours before analysis by immunohistochemistry and confocal microscopy. Actin was stained using phalloidin/Alexa-488 (green), and tubulin was stained using anti-tubulin/phycoerythrin (red). Bar represents 5 uM.

    Blood 2011 17(26), 7145-54. ABT-737 purchased from Selleck.

  • Analysis of SW480 and SW620 cell sensitivity to the BH3-mimetic ABT-737. (a, b) Percentage of apoptosis in adherent or suspended SW480 (a) or SW620 (b) cells cultured in the presence (ABT-737) or absence (ctrl) of ABT-737 (1 uM).

    Cell death dis 2013 4, e801. ABT-737 purchased from Selleck.

    Bcl-XL/Bcl-2 inhibitor ABT-737 aggravates the proapoptotic effects of IL-1IFN-. INS-1E cells were transfected with single or smart Pool PUMA siRNAs and exposed to ABT-737 for 24 h. At this time point, cell death was measured by HO/PI, n  3. *, p  0.05; **, p  0.01.
     

     

     

    J Biol Chem 2010 285, 19919-19920. ABT-737 purchased from Selleck.

  • Effect of ABT-737 on the cell viability of CCRF-CEM cells by treatments of AY4 (10 μg/ml), TRAIL (0.5 μg/ml), SAHA (1 μM),VPA (1 mM), or ABT-737 (10 μM) alone or in combination for 24 h prior to MTT assay.

     

     

    Apoptosis 2010 15, 1256-1269. ABT-737 purchased from Selleck.

    Upper panel ABT-737 inhibits TFK-1 and EGI-1 cell growth.Cells were exposed to ABT-737 at a concentration ranging from 1 to 50 lM. Following 72 h of incubation, growth inhibition was analyzed by crystal violet assay. Dose–effect plot of ABT-737 treatment is presented.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

  • Lower panel detection of PARP-1, cleaved caspase-9 and caspase-3, BCL-2 and MCL-1 in TFK-1 and EGI-1 cells after 72 h of ABT-737 treatment (1, 3, 10, 25,50 μM). Cell lysates were analyzed on Western blotting.

     

     

    Cancer Chemoth Pharm 2011 67, 557-567. ABT-737 purchased from Selleck.

    3 μM ABT737 inhibited growth and viability of TF-1 cells and potentiated proapoptotic effects of 1 μM BIO after 72 hours treatment. TF-1 cells treated with both drugs exhibited more apoptotic cells compared to those treated with each single drug. ABT737 abrogated the protection from BIO-induced apoptosis provided by MS5 coculture.

     

     

    Exp Hematol 2010 38, 908-921. ABT-737 purchased from Selleck.

  • GSIXII synergized with ABT-737 to trigger apoptosis in breast cancer cells . Breast cancer cell lines were incubate d for 48 hours with 10μM GSIXII or DMSO (Ct) in combination or not with ABT-737, 1 μM. Then apoptosis was evaluated with Apo2.7 or Annexin-V staining and flow-cytometry analysis. Represented data are the means of positive cells ± SEM, from three independent experiments.(A) Suboptimal concentrations of GSIXII (5 μM) and 1 μM ABT-737 were used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with mock-treated condition. (B) The 20 μM SAHM1 was used alone or in combination in MFU assay in MCF7 and BT549 cell lines. Results were obtained from three independent experiments and compared with the mock-treated condition.

    Biochem Biophys Res Commun 2013 408, 344-9. ABT-737 purchased from Selleck.

    Apoptosis induced by BCL2-inhibitors in P-glycoprotein expressing cells. MDCKII wild type or MDR1 cells were exposed to different concentrations of ABT-737 (C) or ABT-263 (D) for 24 h before apoptosis was assessed by flow cytometry using externalization of phosphatidylserine.

    Biochem Biophys Res Commun 2012 408, 344-9. ABT-737 purchased from Selleck.

  • MEF wt and MEF Mcl-1 ko mice activating active caspase-3 using 1um ABT for 24h

     

     

    Dr. Arnim Weber of Medizinische Mikrobiologie und Hygiene Universitatsklinikum Freiburg. ABT-737 purchased from Selleck.

    MDB-MA-231 cells were exposed to 30 um cisplatin in the absence or in thepresence of 100nm ABT-737.The cell were stained with Hoechst 33342,MitoTracker Red and Yo-pro-1.

     

     

    Dr. Zhang of Tianjin Medical University. ABT-737 purchased from Selleck.

Purity & Quality Control

Choose Selective Bcl-2 Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description ABT-737 is a BH3 mimetic inhibitor of Bcl-xL, Bcl-2 and Bcl-w with EC50 of 78.7 nM, 30.3 nM and 197.8 nM in cell-free assays, respectively; no inhibition observed against Mcl-1, Bcl-B or Bfl-1. Phase 2.
Features First-generation inhibitor of anti-apoptotic Bcl-2 proteins.
Targets
Bcl-2 [1]
(Cell-free assay)
Bcl-xL [1]
(Cell-free assay)
Bcl-w [1]
(Cell-free assay)
Bcl-B [1]
(Cell-free assay)
Bfl-1 [1]
(Cell-free assay)
30.3 nM(EC50) 78.7 nM(EC50) 197.8 nM(EC50) 1.82 μM(EC50) >10 μM(EC50)
In vitro

ABT-737 shows low activity to Bcl-B and no effects to Mcl-1 and BFL-1. ABT-737 is sensitive to HL60, KG1 and NB4 cells with IC50 of 50 nM, 80 nM and 80 nM, respectively. ABT-737 induces apoptosis in HL60 cells, which due to decreased Bcl-2/Bax heterodimerization and has no effect on cell cycle distribution. ABT-737 also induces cytochrome c release from purified mitochondria and promotes conformational changes in Bax that are associated with apoptosis. [1] Resistant cells (Hela and MCF-7) can be sensitized to ABT-737 by approaches that down-regulate, destabilize, or inactivate Mcl-1. ABT-737 also causes Bax/BAK-dependent cytochrome c release only when Mcl-1 has been neutralized. [2] ABT-737 displaces Bim from Bcl2's BH3-binding pocket, allowing Bim to activate Bax, induce mitochondrial permeabilization, and rapidly commit the primary chronic lymphocytic leukemia (CLL) cells to death. [3] Knockdown of Mcl-1 with siRNA sensitizes two resistant SCLC cell lines H196 and DMS114 to ABT-737 by enhancing the induction of apoptosis. Likewise, up-regulation of Noxa sensitizes H196 cells to ABT-737. ABT-737 inhibits proliferation and induces apoptosis in many SCLC cell lines including NCI-H889, NCI-H1963, NCI-H1417, NCI-H146 and etc. Bcl-2 and Noxa may contribute mechanistically to the cellular response to ABT-737 in NCI-H146 cells. [4] A recent study shows that ABT-737 significantly induces apoptosis in HTLV-1 infected T-cell lines as well as in fresh ATLL cells. [5]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
OCI-Ly1  MUfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NUT6VIJMOjVyIH7NxsA> NV3sb295PzJiaB?= NWnpXZJDTE2VTx?= Mnv5Z4F2e2WmIEm3KUBtd3O|IH;mJJZq[WKrbHn0fUBqdiClZXzsd{B1emGwc3\lZ5Rm\CC5aYToJGJEVDZic3nSUmE> M4TNUFI3PjV5Mki4
KG1a MnrUR4VtdCCYaXHibYxqfHliQYPzZZk> MmSyNE0yOCEQvF2= M4DnO|I1KGh? MonoSG1UVw>? MVvJR|UxRTdwNkig{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2rhdVI3PTV{N{Gy
Kasumi-1 Mn7OR4VtdCCYaXHibYxqfHliQYPzZZk> NX\HbodJOC1zMDFOwG0> M3XSSVI1KGh? MYfEUXNQ MYjJR|UxRTRwOEeg{txONCCmZXPy[YF{\XNiY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M{HKSVI3PTV{N{Gy
KG1a NV62cYY{SXCxcITvd4l{KEG|c3H5 NHrWPIgxNTFyIN88US=> MXKyOEBp M3\ZfmROW09? NEXjUXVqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NF71XZMzPjV3MkexNi=>
Kasumi-1 MXLBdI9xfG:|aYOgRZN{[Xl? NG\pOpcxNTFyIN88US=> Mni1NlQhcA>? NH3nc49FVVOR NG\GVVFqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWXGc4Y4OjZ3NUK3NVI>
MC-3  NE\2d3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkLWOU8yOC9{MDFOwG0> MXKyOEBp MWHEUXNQ NXXIelg3cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NULnemtUOjZ2NEe2NVU>
HN22  NVvBdJhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXT6RYhrOi53L{euOU8zOi53IN88US=> NWHTUXhlOjRiaB?= NEnB[2tFVVOR NWjkUZJFcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MX:yOlQ1PzZzNR?=
MC-3  NHjTfW9CeG:ydH;zbZMhSXO|YYm= MnW0OU8yOC9{MDFOwG0> Ml7QNlQhcA>? NGXWfWdFVVOR MlPPbY5lfWOnczDjZZNx[XOnLX3l[IlifGWmIHHwc5B1d3Orcx?= M1uwTVI3PDR5NkG1
HN22  NWP2flN6SXCxcITvd4l{KEG|c3H5 Mlm3Nk42NzdwNT:yNk42KM7:TR?= NUPy[5k6OjRiaB?= M2XCdWROW09? MWjpcoR2[2W|IHPhd5Bie2VvbXXkbYF1\WRiYYDvdJRwe2m| M4TB[VI3PDR5NkG1
MOLT-4 NFvxSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGK4enYyOC13MECwJI5O NH\1e4Q4OiCq NXrXN5g5TE2VTx?= M4q3dmlEPTB;MD6xPVgh|ryP NWLHcGk{OjZ|OUKzN|I>
RS4;11 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PZRVExNTVyMECgcm0> NFLjRWI4OiCq Mn\xSG1UVw>? NWHQcG1XUUN3ME2wMlAxOiEQvF2= NVv5d3NWOjZ|OUKzN|I>
JURKAT NF\IeWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjBb48yOC13MECwJI5O Mke5O|IhcA>? MV7EUXNQ M4rZfWlEPTB;Nk[g{txO MWmyOlM6OjN|Mh?=
CEM R NHzIUFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSxNE02ODByIH7N M2HONVczKGh? NWPDbFVpTE2VTx?= M1roWGlEPTB;NT60JO69VQ>? MmHXNlY{QTJ|M{K=
CEM S NXfZcJhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPheplZOTBvNUCwNEBvVQ>? M2rFNlczKGh? Ml;VSG1UVw>? Mmq4TWM2OD1zMj6xJO69VQ>? M2PqS|I3Ozl{M{Oy
MOLT-4 M4q1emFxd3C2b4Ppd{BCe3OjeR?= NGnpVFEyOC1zMECwJI5O Mlf3NlQhcA>? NXHKVIhMTE2VTx?= NGXkeIlk[XW|ZYOgeIhmKGOuZXH2ZYdmKG:oIFLjcE0zKGGwZDD0bIUh\G:5boLl[5Vt[XSrb36gc4YhSmOuLYjMJIFv\CCPY3ytNS=> MYeyOlM6OjN|Mh?=
CEM S Mm\KRZBweHSxc3nzJGF{e2G7 MXmxNE0yODByIH7N MkHnNlQhcA>? M3XsdmROW09? MnTkZ4F2e2W|IITo[UBkdGWjdnHn[UBw\iCEY3ytNkBidmRidHjlJIRwf26{ZXf1cIF1cW:wIH;mJGJkdC26TDDhcoQhVWOuLUG= MUeyOlM6OjN|Mh?=
JURKAT MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF6yPIQyODBvMUCwNEBvVQ>? M{jwc|Q5KGh? NVnVbHZJTE2VTx?= MlrMTWM2OD17NUZCtVkvOyCwTR?= NUj3b41oOjZzN{KyOlk>
LOUCY MoC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\xbIRNOTByLUGwNFAhdk1? M{LsN|Q5KGh? NUjvc5FMTE2VTx?= MkPFTWM2OD1|Mj64xtEyOC57IH7N NX7FfYpbOjZzN{KyOlk>
WM-115 Mli0R4VtdCCYaXHibYxqfHliQYPzZZk> MnTmNVAxyqCwTR?= NF\P[444OiCq M1fFOIVvcGGwY3XzJIN2emO3bXnuMYlv\HWlZXSgZY51cS2|dYL2bZZidMLi NXTVd4dXOjZzMU[3O|Y>
B16 MYLD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1\PVVExOMLibl2= M3\sW|czKGh? Ml;X[Y5p[W6lZYOgZ5Vz[3WvaX6tbY5lfWOnZDDhcpRqNXO3co\peoFtyqB? NF[yb5gzPjFzNke3Oi=>
HL-60  M1rJRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;mNWRrPzJiaB?= Mnz4TWM2OMLiPTCxNE44KG6P MnH2NlYxPDV4MEm=
MOLM-13  M1Hjc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXS3NkBp MmD6TWM2OMLiPTCyO{46KG6P MnX5NlYxPDV4MEm=
OCI-AML3 NWrkV5Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWi3NkBp MlvDTWM2OMLiPTCxPVUxKG6P M1fxNlI3ODR3NkC5
BCWM.1 NHLZUFBCeG:ydH;zbZMhSXO|YYm= NFHwOosxNTFwNjFOwG0> NWHFc4dpOjRiaB?= NHPmbZFqdmS3Y3XzJINmdGxiYYDvdJRwe2m| MkPKNlU5QTN{OUC=
MWCL-1 Mnj2RZBweHSxc3nzJGF{e2G7 MUKwMVEvPiEQvF2= MoKxNlQhcA>? NH7kUo5qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M{DPXFI2QDl|Mkmw
MM.1s MmCwRZBweHSxc3nzJGF{e2G7 MVSwMVEvPiEQvF2= M1fFVVI1KGh? M1XZb4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NYLTTGR6OjV6OUOyPVA>
HCT116 MlXrSpVv[3Srb36gRZN{[Xl? M3O1OlMwOTBizszN M3LXPVEzyqCqwrC= NYC5WlFtTE2VTx?= NV64SIxxcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JIlv[3KnYYPlJIlvKEyFM1KtTWkh[2:wdnXyd4lwdiCjbnSgV3FUXE1zIHTl[5Ji\GG2aX;u NVLwepJOOjV5MUWwNlg>
HCT116 BAX BAK1 DKO MnLySpVv[3Srb36gRZN{[Xl? M3\F[|MwOTBizszN NW\tWWNTOTMEoHlCpC=> M3TJTWROW09? NIqzU2pqdmS3Y3XzJIEh\G:|ZT3k[ZBmdmSnboSgbY5kemWjc3WgbY4hVEN|Qj3JTUBkd264ZYLzbY9vKGGwZDDTVXNVVTFiZHXndoFl[XSrb36= NF;oTlYzPTdzNUCyPC=>
HCT116 NX3R[5FSTnWwY4Tpc44hSXO|YYm= NGTmVFcyOCEQvF2= NFjMbGoyOsLiaNMg M2\5ZmROW09? M1qx[olv[3KnYYPld{BITlBvTFOzRkBxfW6ldHG= NUHFNWtzOjV5MUWwNlg>
HCT116 BAX BAK1 DKO NHfofWtHfW6ldHnvckBCe3OjeR?= MWOxNEDPxE1? NFzQPFAyOsLiaNMg M4jJe2ROW09? MmXEbY5kemWjc3XzJGdHWC2OQ{PCJJB2dmO2YR?= MVmyOVcyPTB{OB?=
HCT116 NUXz[FN[SXW2b4DoZYd6KEG|c3H5 MYexNEDPxE1? M3PMOlEzyqCqwrC= MnnFSG1UVw>? NITLe3ZqdmS3Y3XzJIEh[2:vcHzleIUh[XW2b4DoZYdq[yC{ZYPwc45{\Q>? NYLWe3Y2OjV5MUWwNlg>
HCT116 BAX BAK1 DKO NXXDV5dXSXW2b4DoZYd6KEG|c3H5 NILaWZcyOCEQvF2= MVqxNuKhcMLi NHLtRmtFVVOR M1nmeYlv\HWlZYOgZUBkd22ybHX0[UBifXSxcHjh[4lkKHKnc4DvcpNm MVqyOVcyPTB{OB?=
U937 NIPicnRCeG:ydH;zbZMhSXO|YYm= MU[wMlEzPS1{IN88US=> NVPiNVRmOjRiaB?= M1\E[IVvcGGwY3XzJGRJSS:[LUGxMYlv\HWlZXSgZZBweHSxc3nz MVGyOVcyPDB{NB?=
U937  NUixcop1SXCxcITvd4l{KEG|c3H5 M1rIWFAvPSEQvF2= MmLvNlQhcA>? M2fafYVvcGGwY3XzJINt\WG4YXflJI9nKFCDUmCgZY5lKGOjc4Dhd4UuOyCjczD3[YxtKGG|IF7vfIEhdGW4ZXy= MmDONlU4OTRyMkS=
HL-60 AAA-Bcl-2 NVzIc483SXCxcITvd4l{KEG|c3H5 MUmwMVUh|ryP MkezOFghcA>? MnfMTWM2OD1yLki3JO69de,:jHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MYqyOVcyOTR4MB?=
HL-60 EEE-Bcl-2 MkToRZBweHSxc3nzJGF{e2G7 NY\3Z5I6OC13IN88US=> NHzuc4Q1QCCq NGfPUY5KSzVyPUWg{txu97zOIHnu[JVk\XNiY3XscEBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> NHHWfIczPTdzMUS2NC=>
U87 NWHPbmpsTnWwY4Tpc44hSXO|YYm= MlziOVAh|ryP MUmyOEBp M3rtN5Jm\HWlZYOgeIhmKG2UTlGg[ZhxemW|c3nvckBt\X[nbIOgc4YhVU2SLUKsJG1OWC1zNDDhcoQhSmOuLUK= NGTmPGMzPTZ4N{[2Ny=>
K562 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M2LrdVEuOTBizszN M2XrdVQ5KGh? MonySG1UVw>? NF[3b4xKSzVyPUK2Mlch|ryP MUOyOVU6PjV4MR?=
K562/Mcl -1-IRESBim M2Drdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVmwe4JyUUN3ME25MlMh|ryP NFfib2kzPTV|NUmwNC=>
K562/Bcl- 2-IRESBim NIiyVphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlLHTWM2OD1yLkO1JO69VQ>? NFHnepIzPTV|NUmwNC=>
Jurkat NHu2T4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofzTWM2OD1yLk[2JO69VQ>? NFLwO4IzPTV|NUmwNC=>
JurkatΔBak NX;LcpdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nPZ2lEPTB-NUCg{txO NU[zTHc3OjV3M{W5NFA>
HL60/VCR NFzQfFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3mzXmlEPTB-MUCwJO69VQ>? NG\XfW8zPTV|NUmwNC=>
Kasumi-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HpeGlEPTB;MD6wNUDPxE1? M4OwclI2PTN3OUCw
Kasumi-1/ABT NYrLN41WT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwNUGg{txO NYi3fIhlOjV3M{W5NFA>
THP-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUX6Z2Q1UUN3ME2xMlI4KM7:TR?= MV2yOVU{PTlyMB?=
U937 NGXORVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fVSGlEPTB;NT6yPUDPxE1? NEfVOZkzPTV|NUmwNC=>
C1498 NFfQV|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTNTWM2OD14LkGzJO69VQ>? MkTNNlU2OzV7MEC=
RPMI 8226 NWK3U3NXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXCTWM2OD1yLkK1JO69VQ>? MmnyNlU2OzV7MEC=
MM.1S MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjKS29RUUN3ME2wMlQxKM7:TR?= MU[yOVU{PTlyMB?=
NCI-H929 NXmze4xQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;RTWM2OD1zNT6yNUDPxE1? M{X0XVI2PTN3OUCw
U266 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnvfmd3UUN3ME2wMlY5KM7:TR?= NH\wVVkzPTV|NUmwNC=>
MCF-7 Mnr2R4VtdCCYaXHibYxqfHliQYPzZZk> MnvXOUDPxE1? MX:0PEBp MmPjSG1UVw>? Mnfm[Y5p[W6lZYOgeIhmKHOnboPpeIl3cXS7IITvJI9zKHKjZHnheIlwdg>? M3fKe|I2PDB7MUK0
MCF-7 MoWxRZBweHSxc3nzJGF{e2G7 M1PZbVUh|ryP NH7kfpU1NzJ2L{S4JIg> Mnu1SG1UVw>? NYj0eXpicW6lcnXhd4V{KHSqZTDjcIVifmWmIGDBVnA> M1TJXlI2PDB7MUK0
MCF-7 Ml7ZSpVv[3Srb36gRZN{[Xl? NX;xVnkzPSEQvF2= M4HEVlI1KGh? MlTQSG1UVw>? NIPHXppmdmijbnPld{B1cGWuZY\lcEBw\iCPY3ytNUBmgHC{ZYPzbY9vyqB? MmfJNlU1ODlzMkS=
MDA-MB 231  MYLGeY5kfGmxbjDBd5NigQ>? M3\seFUh|ryP MXmyOEBp NGW3e3VFVVOR M4P1[oVvcGGwY3XzJJRp\WyndnXsJI9nKE2lbD2xJIV5eHKnc4Ppc47DqA>? M1vYPVI2PDB7MUK0
ZR-75-1  M4DmVmZ2dmO2aX;uJGF{e2G7 NVPuOmFCPSEQvF2= NHfWN2czPCCq MmnwSG1UVw>? MXzlcohidmOnczD0bIVt\X[nbDDv[kBO[2xvMTDlfJBz\XO|aX;uxsA> M3TDWVI2PDB7MUK0
A549 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NFTXcHoxNTJyIN88US=> NXfxZ29EPzJiaB?= NIO1[JRFVVOR M4jzVYRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? NI\sT2EzPTN6OEe2Ni=>
H1299 NVm2XFRwS2WubDDWbYFjcWyrdImgRZN{[Xl? NH7FenExNTJyIN88US=> NHuzUGo4OiCq MYXEUXNQ MonB[IVkemWjc3XzJJRp\SClZXzsJJN2en[rdnHsJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXyJINwdWKrbnXkJJdqfGhiYYPwbZJqdg>? NXvrNWlzOjV|OEi3OlI>
HO-8910 NIHCRmlE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M3LJclAuOjBizszN MmjmO|IhcA>? M2fodmROW09? M1fwSIRm[3KnYYPld{B1cGViY3XscEB{fXK4aY\hcEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldkBkd22kaX7l[EB4cXSqIHHzdIlzcW5? M4fVRVI2Ozh6N{[y
HT-29 NGntOlNE\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnrVNE0zOCEQvF2= MV:3NkBp MVXEUXNQ NVLETYVx\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= MmrpNlU{QDh5NkK=
HCT-116 MmX1R4VtdCCYaXHibYxqfHliQYPzZZk> M{Lud|AuOjBizszN NHf3bWE4OiCq MXXEUXNQ NWTTOoZT\GWlcnXhd4V{KHSqZTDj[YxtKHO3co\peoFtKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVzKGOxbXLpcoVlKHerdHigZZNxcXKrbh?= M1PZSFI2Ozh6N{[y
A549 M4XNfmFxd3C2b4Ppd{BCe3OjeR?= NWDXc4RlOjBizszN NGXOdY01QCCq MnnPSG1UVw>? NYL4VIw6cW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueTDjc41jcW6nZDD3bZRpKGG|cHnybY4> MXKyOVM5QDd4Mh?=
H1299 NX;ad2RuSXCxcITvd4l{KEG|c3H5 MUCyNEDPxE1? MUi0PEBp NVe5WFd5TE2VTx?= MVPpcoR2[2W|IHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGOxbXLpcoVlKHerdHigZZNxcXKrbh?= NWXQSJlFOjV|OEi3OlI>
Sc-1 MkPiR4VtdCCYaXHibYxqfHliQYPzZZk> NF3ESlkxNjByMEGtNUDPxE1? NECxcYs6PiCq MYLk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NVLNTWFqOjV|N{O1NFg>
OcI-LY18 M4LNWmNmdGxiVnnhZoltcXS7IFHzd4F6 MVWwMlAxODFvMTFOwG0> NUnrNINuQTZiaB?= M2rtXIRm[3KnYYPld{B1cGViY3XscEB3cWGkaXzpeJkhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> MVKyOVM4OzVyOB?=
RL  M{\XO2NmdGxiVnnhZoltcXS7IFHzd4F6 NXfPNmg3OC5yMECxMVEh|ryP Mnf2PVYhcA>? MYPk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy M330TFI2Ozd|NUC4
RKO M3jLfmNmdGxiVnnhZoltcXS7IFHzd4F6 MmXnNE0yOCEQvF2= MWiyOQKBkWkEoB?= MUnEUXNQ MlrSTWM2OD8kgJmyOgKBkcL3TR?= NXXxWXhROjV|MESzPFM>
Caco-2 MkDsR4VtdCCYaXHibYxqfHliQYPzZZk> NVLvVWRLOC1zMDFOwG0> NYHwPWxmOjUkgJnoxsA> NXzkdphITE2VTx?= MlnjTWM2OD1zOT635qCKyrWP MVmyOVMxPDN6Mx?=
DLD1 MWfD[YxtKF[rYXLpcIl1gSCDc4PhfS=> MWiwMVExKM7:TR?= MnvhNlTjiImqwrC= NHTKdpZFVVOR NHPOV2RKSzVyPUG4Mlc56oDLwsXN M1m4c|I2OzB2M{iz
LS411N M3m0bmNmdGxiVnnhZoltcXS7IFHzd4F6 NYTOXpNKOC1zMDFOwG0> NHzMTW0zPOLCiXlCpC=> NYPOTHVTTE2VTx?= MVnJR|UxRTFzLkS35qCKyrWP NFPteJAzPTNyNEO4Ny=>
SW620 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M3zsNFAuOTBizszN MnWyNlTjiImqwrC= NH2wVWxFVVOR MYPJR|UxRTF{LkK05qCKyrWP M1HUWFI2OzB2M{iz
HCT116 MXnD[YxtKF[rYXLpcIl1gSCDc4PhfS=> M1TNT|AuOTBizszN Ml3uNlTjiImqwrC= MVHEUXNQ NGCwT|RKSzVyPUKwMlQ66oDLwsXN MoDBNlU{ODR|OEO=
HaCaT MUXD[YxtKF[rYXLpcIl1gSCDc4PhfS=> NU\wWWdzOC5zL{GvNVAh|ryP MW[yOEBp M1jSbGROW09? M2LlUIRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MWeyOVIyODd7NR?=
A5-RT3 NVLQdGt7S2WubDDWbYFjcWyrdImgRZN{[Xl? MWewMlEwOS9zMDFOwG0> NWS4WZMyOjRiaB?= MVPEUXNQ NWnhW4JG\GWlcnXhd4V{KGOnbHygeoli[mmuaYT5JIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NWLub4s2OjV{MUC3PVU>
HaCaT NW\3VVJrTnWwY4Tpc44hSXO|YYm= NVvsWWVsOTEkgJpOwG0> NWTBcolVOjRxNEigbC=> NHPTU|BFVVOR NGHhOplqdmS3Y3XzJG1OWCCjbnSgSG5CKG[{YXft[Y51[XSrb36= M2TLV|I2OjFyN{m1
A5-RT3 MV7GeY5kfGmxbjDBd5NigQ>? M{\D[|Ex6oDLzszN NEXRNYMzPC92ODDo NHvGWlFFVVOR Ml34bY5lfWOnczDNUXAh[W6mIFTORUBnemGpbXXueIF1cW:w M3TZdVI2OjFyN{m1
A5-RT3 NH6wOlJHfW6ldHnvckBCe3OjeR?= NFHNc2o2KM7:TR?= MVS2JIg> MXnEUXNQ MoDCbY5lfWOnczD0bIUhemWuZXHz[UBw\iCvaYTvZ4hwdmS{aXHsJJBzd3SnaX7zJIFv\CC{ZXT1Z4V{KGOub37v[4VvcWNic4Xyeol3[WxiaX6gZUBk[XOyYYPlMYlv\GWyZX7k[Y51KG2jbn7ldi=> MknWNlUzOTB5OUW=
U266 MmW1SpVv[3Srb36gRZN{[Xl? NF\NZWw2ODBxN{WwJI5O NYHL[21kOjRxNEigbC=> M{T6bGROW09? Mofi[I94dnKnZ4XsZZRmeyCEaX2sJJBzcW6laYDhcIx6KHSqZTDFUEBqe2:ob4Lt MmjjNlUzODh6OEi=
RPMI8226 NVnI[JN[TnWwY4Tpc44hSXO|YYm= MnWxOVAxNzd3MDDuUS=> NV64WG1jOjRxNEigbC=> NYjaUJNmTE2VTx?= NFHDWmlld3ewcnXneYxifGW|IFLpcUwheHKrbnPpdIFtdHlidHjlJGVNKGm|b3\vdo0> M4HiPFI2OjB6OEi4
MM.1S M2rQXGZ2dmO2aX;uJGF{e2G7 NWLiUo11PTByL{e1NEBvVQ>? NEL2fGozPC92ODDo M2G3c2ROW09? NUjnR3B[\G:5boLl[5Vt[XSnczDCbY0tKHC{aX7jbZBidGy7IITo[UBGVCCrc3;mc5Ju MVGyOVIxQDh6OB?=
Clone A M4X5XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYKwMlLjiJN4MDFOwG0> NIHzS5k4OiCq NEnXTHlFVVOR Ml;ZTWM2OD15LkWg{txO MVKyOVIxQDh6Mh?=
CX-1 Mn[1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnmcJZmOC5{4pETOlAh|ryP NXHUbFF[PzJiaB?= MWHEUXNQ Ml7mTWM2OD1zLkig{txO NX7KU|E6OjV{MEi4PFI>
LS174T NXjlUnpyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrBNE4z6oDVNkCg{txO M1G3PVczKGh? NGW1UWNFVVOR MVHJR|UxRTF6LkOg{txO MWWyOVIxQDh6Mh?=
HT29 MUfBdI9xfG:|aYOgRZN{[Xl? NEnlOYoyNzVxMUCg{txO MkT0OFghcA>? M{SzVYNifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NGfhT|EzPTF7MkG4PC=>
SW480 M4XlNGFxd3C2b4Ppd{BCe3OjeR?= M2[5SlEwPS9zMDFOwG0> MX[0PEBp M{TXb4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy NE\GcnQzPTF7MkG4PC=>
Colo205 MUjBdI9xfG:|aYOgRZN{[Xl? MVqxM|UwOTBizszN M2K3clQ5KGh? MkjQZ4F2e2W|IHPlcIwh\GWjdHigbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK= M4PtVlI2OTl{MUi4
Caco2 NFj1[2dCeG:ydH;zbZMhSXO|YYm= MnzmNU82NzFyIN88US=> MUe0PEBp M2Dwe4NifXOnczDj[YxtKGSnYYToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy MmPsNlUyQTJzOEi=
PCI-13 MlfDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYe3NkBp NGeyXZZFVVOR M37pfmdKPTB;MUWgxtEhOS56IN88US=> M2L4[|I2OTN7M{i3
PCI-15B M{Ppdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjPeZM4OiCq NX70R|BjTE2VTx?= MXjHTVUxRTFzINMxJFQvPSEQvF2= MVSyOVE{QTN6Nx?=
UM-SCC22B NHvLdFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTXelc4OiCq M{fDZWROW09? NFXhZYtIUTVyPUG5JOKyKDJwOTFOwG0> MXKyOVE{QTN6Nx?=
UM-SCC47 NHi1VmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DE[FczKGh? Mkj2SG1UVw>? M1LCV2dKPTB;MUmgxtEhOTJwMzFOwG0> MUiyOVE{QTN6Nx?=
93-VU-147T Mn7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7UbXM4OiCq NVO2fGRVTE2VTx?= NV;ZWndvT0l3ME20MlMhyrFiMz61JO69VQ>? NYDmVXN{OjVzM{mzPFc>
UD-SCC2 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4DMZVczKGh? NVf4WHplTE2VTx?= NYjWN4oyT0l3ME2yPEDDuSB{Lkmg{txO Mmr3NlUyOzl|OEe=
UPCI:SCC90 Mn7vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVi3NkBp M2\HeWROW09? M{DUeGdKPTB;Nj62JOKyKDFwNTFOwG0> MVmyOVE{QTN6Nx?=
RPMI-8226  MX7D[YxtKF[rYXLpcIl1gSCDc4PhfS=> MofSNVI2NzJ3MD:1NFAhdk1? MWK0PIjDqA>? MYrEUXNQ MUfk[YNz\WG|ZYOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? MWOyOVAxQDJyMh?=
OPM-2  MkLuR4VtdCCYaXHibYxqfHliQYPzZZk> MXSxNlUwOjVyL{WwNEBvVQ>? M{PQTlQ5cMLi MnLLSG1UVw>? Mn3X[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MYWyOVAxQDJyMh?=
RPMI-8226  M4TrbmFxd3C2b4Ppd{BCe3OjeR?= M2K5bFEzPS9{NUCvOVAxKG6P NEHGbHo1QGkEoB?= MoGxSG1UVw>? MUDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz Mmi4NlUxODh{MEK=
OPM-2  NU\aXoxLSXCxcITvd4l{KEG|c3H5 NXPKd2NnOTJ3L{K1NE82ODBibl2= NVPQfZpSPDiqwrC= MVvEUXNQ MXHpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NYrvbG5nOjVyMEiyNFI>
COG-LL-319 MnzxSpVv[3Srb36gRZN{[Xl? NETpbpUyODBibl2= NHu3UFUyNzNxNjDo MUDEUXNQ MXjpcoR2[2W|IHPhd5Bie2VvZHXw[Y5l\W62IF3jcE0yKGOuZXH2ZYdm M3XsUFI1QTVzNEey
RS4;11 M1frNWZ2dmO2aX;uJGF{e2G7 Ml32NVAxKG6P NHfNO2QyNzNxNjDo NYjxRXFzTE2VTx?= NXL2Z3RxcW6mdXPld{Bk[XOyYYPlMYRmeGWwZHXueEBO[2xvMTDjcIVifmGpZR?= NFzyWHUzPDl3MUS3Ni=>

... Click to View More Cell Line Experimental Data

In vivo In aggressive leukemia model, ABT-737 suppresses the leukemia burden by 53% at the 30 mg/kg, with significantly extended survival of mice. ABT-737 does not induce significantly abnormalities in blood cell counts or serum chemistries. [1] ABT-737 prolongs the survival of recipient mice transplanted with Bcl-2-transduced tumors. [2] ABT-737 shows great antitumor activity in an ATLL mouse model at a dose of 100 mg/kg. [5]

Protocol

Kinase Assay
+ Expand

Fluorescence polarization assays:

Binding affinity of GST-Bcl-2 family proteins to the FITC-conjugated BH3 domain of Bim (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is determined. Briefly, 100 nM of GST-Bcl-2 family fusion proteins are incubated with serial dilutions of ABT-737 in PBS for 2 min. Then, 20 nM of FITC-Bim BH3 peptide (FITC-Ahx-DMRPEIWIAQELRRIGDEFNAYYAR) is added. Fluorescence polarization is measured using an Analyst TM AD Assay Detection System after 10 min using the 96-well black plate. Then IC50 are determined.
Cell Research
+ Expand
  • Cell lines: SCLC cell lines NCI-H889, NCI-H1963, NCI-H1417, NCI-H146, NCI-187, DMS79, NCI-1048, NCI-H82, NCI-H196, H69AR, and DMS114
  • Concentrations: 0.001-10 μM
  • Incubation Time: 48 hours
  • Method:

    SCLC cells are treated for 48 hours in 96-well tissue culture plates in a total volume of 100 μL tissue culture medium supplemented with 10% human serum. Viable cells are determined using the MTS assay.


    (Only for Reference)
Animal Research
+ Expand
  • Animal Models: Scid mice injected with Luc-expressing FD/ΔRaf-1:ER cells
  • Formulation: 1 g/mL stock solution of ABT-737 in DMSO is added to a mixture of 30% propylene glycol, 5% Tween 80, 65% D5W (5% dextrose in water) (pH 4−5; final concentration of DMSO ≤ 1%)
  • Dosages: 20 and 30 mg/kg
  • Administration: For intraperitoneal (i.p.) every day
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 100 mg/mL (122.93 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 30% Propylene glycol, 5% Tween 80, 65% D5W 30mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 813.43
Formula

C42H45ClN6O5S2

CAS No. 852808-04-9
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    What’s the recommended method about reconstitution of the compound for in vivo animal study?

  • Answer:

    For oral administration, we suggest the vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W, at up to 30mg/ml; For injection, ABT-737 can be dissolved in 2% DMSO/50% PEG 300/5% Tween 80/ddH2O at 2.5 mg/ml.

Bcl-2 Signaling Pathway Map

Bcl-2 Inhibitors with Unique Features

Related Bcl-2 Products

Tags: buy ABT-737 | ABT-737 supplier | purchase ABT-737 | ABT-737 cost | ABT-737 manufacturer | order ABT-737 | ABT-737 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID